Development of thermoreversible in situ Nasal Gel using chitosan as a mucoadhesive agent for prophylaxis of migraine

Siddhesh Ghatwal, Divya Harmalkar, Soraiya Godinho, Lalit Kumar, Rupesh K. Shirodkar

Research output: Contribution to journalArticle

Abstract

The aim of the current study was to formulate and characterise thermoreversible in situ nasal gels of flunarizine dihydrochloride (FDCL) for prophylaxis of migraine. FDCL was complexed with β-cy-clodextrin (1:1 ratio) to enhance its solubility. A mucoadhesive polymer, chitosan was used to increase nasal residence time of the drug. Gels were formulated by cold technique using poloxamer 188 and poloxamer 407. Drug content was determined before and after gelation. Optimised formulation exhibited 89.41% of in vitro drug release at the end of 6 h. In vitro release kinetics results demonstrated that all the prepared formulations released the drug by following first-order kinetics. Short term stability study revealed 5 ± 3 °C as the appropriate storage condition for the formulations. Thus, the study proved that thermoreversible in situ nasal gel of FDCL with mucoadhesive agent could be a promising initiative for the treatment of migraine.

Original languageEnglish
Pages (from-to)2365-2372
Number of pages8
JournalLatin American Journal of Pharmacy
Volume37
Issue number12
Publication statusPublished - 01-01-2018

Fingerprint

Flunarizine
Chitosan
Migraine Disorders
Nose
Poloxamer
Gels
Drug Compounding
Pharmaceutical Preparations
Solubility
Polymers
In Vitro Techniques

All Science Journal Classification (ASJC) codes

  • Pharmaceutical Science
  • Drug Discovery

Cite this

Ghatwal, Siddhesh ; Harmalkar, Divya ; Godinho, Soraiya ; Kumar, Lalit ; Shirodkar, Rupesh K. / Development of thermoreversible in situ Nasal Gel using chitosan as a mucoadhesive agent for prophylaxis of migraine. In: Latin American Journal of Pharmacy. 2018 ; Vol. 37, No. 12. pp. 2365-2372.
@article{dbb68f03b4c14e6a8a585a3c377ae700,
title = "Development of thermoreversible in situ Nasal Gel using chitosan as a mucoadhesive agent for prophylaxis of migraine",
abstract = "The aim of the current study was to formulate and characterise thermoreversible in situ nasal gels of flunarizine dihydrochloride (FDCL) for prophylaxis of migraine. FDCL was complexed with β-cy-clodextrin (1:1 ratio) to enhance its solubility. A mucoadhesive polymer, chitosan was used to increase nasal residence time of the drug. Gels were formulated by cold technique using poloxamer 188 and poloxamer 407. Drug content was determined before and after gelation. Optimised formulation exhibited 89.41{\%} of in vitro drug release at the end of 6 h. In vitro release kinetics results demonstrated that all the prepared formulations released the drug by following first-order kinetics. Short term stability study revealed 5 ± 3 °C as the appropriate storage condition for the formulations. Thus, the study proved that thermoreversible in situ nasal gel of FDCL with mucoadhesive agent could be a promising initiative for the treatment of migraine.",
author = "Siddhesh Ghatwal and Divya Harmalkar and Soraiya Godinho and Lalit Kumar and Shirodkar, {Rupesh K.}",
year = "2018",
month = "1",
day = "1",
language = "English",
volume = "37",
pages = "2365--2372",
journal = "Latin American Journal of Pharmacy",
issn = "0326-2383",
publisher = "Colegio de Farmaceuticos de la Provincia de Buenos Aires",
number = "12",

}

Development of thermoreversible in situ Nasal Gel using chitosan as a mucoadhesive agent for prophylaxis of migraine. / Ghatwal, Siddhesh; Harmalkar, Divya; Godinho, Soraiya; Kumar, Lalit; Shirodkar, Rupesh K.

In: Latin American Journal of Pharmacy, Vol. 37, No. 12, 01.01.2018, p. 2365-2372.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Development of thermoreversible in situ Nasal Gel using chitosan as a mucoadhesive agent for prophylaxis of migraine

AU - Ghatwal, Siddhesh

AU - Harmalkar, Divya

AU - Godinho, Soraiya

AU - Kumar, Lalit

AU - Shirodkar, Rupesh K.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - The aim of the current study was to formulate and characterise thermoreversible in situ nasal gels of flunarizine dihydrochloride (FDCL) for prophylaxis of migraine. FDCL was complexed with β-cy-clodextrin (1:1 ratio) to enhance its solubility. A mucoadhesive polymer, chitosan was used to increase nasal residence time of the drug. Gels were formulated by cold technique using poloxamer 188 and poloxamer 407. Drug content was determined before and after gelation. Optimised formulation exhibited 89.41% of in vitro drug release at the end of 6 h. In vitro release kinetics results demonstrated that all the prepared formulations released the drug by following first-order kinetics. Short term stability study revealed 5 ± 3 °C as the appropriate storage condition for the formulations. Thus, the study proved that thermoreversible in situ nasal gel of FDCL with mucoadhesive agent could be a promising initiative for the treatment of migraine.

AB - The aim of the current study was to formulate and characterise thermoreversible in situ nasal gels of flunarizine dihydrochloride (FDCL) for prophylaxis of migraine. FDCL was complexed with β-cy-clodextrin (1:1 ratio) to enhance its solubility. A mucoadhesive polymer, chitosan was used to increase nasal residence time of the drug. Gels were formulated by cold technique using poloxamer 188 and poloxamer 407. Drug content was determined before and after gelation. Optimised formulation exhibited 89.41% of in vitro drug release at the end of 6 h. In vitro release kinetics results demonstrated that all the prepared formulations released the drug by following first-order kinetics. Short term stability study revealed 5 ± 3 °C as the appropriate storage condition for the formulations. Thus, the study proved that thermoreversible in situ nasal gel of FDCL with mucoadhesive agent could be a promising initiative for the treatment of migraine.

UR - http://www.scopus.com/inward/record.url?scp=85060929636&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060929636&partnerID=8YFLogxK

M3 - Article

VL - 37

SP - 2365

EP - 2372

JO - Latin American Journal of Pharmacy

JF - Latin American Journal of Pharmacy

SN - 0326-2383

IS - 12

ER -